29 August 2019
Mayne Pharma says the Australian Pharmaceutical Benefits Scheme has approved its Kapanol morphine drug for palliative care chronic breathlessness for reimbursement.
Mayne Pharma said that from September 1, 2019 eligible palliative care patients taking 10mg and 20mg Kapanol sustained release capsules for their advanced chronic breathlessness, would be reimbursed through the Pharmaceutical Benefits Scheme.
The company said the new indication on the PBS palliative care schedule, was in addition to Kapanol’s use in chronic severe disabling pain unresponsive to non-opioid analgesics.
Website link: www.maynepharma.com